HIV: First-in-Class Therapies Target Major Unmet Needs Including Drug Resistance and Latency Reversa

HIV: First-in-Class Therapies Target Major Unmet Needs Including Drug Resistance and Latency Reversal Published on : 06 March 2020

Report Overview Human immunodeficiency virus (HIV) is a chronic disease that can be transmitted through blood, semen, and other bodily fluids by means such as sexual contact, pregnancy and breastfeeding, the sharing of injection drug equipment, and blood transfusions.

As the disease progresses, the virus causes depletion of a type of immune cell known as cluster of differentiation 4 (CD4) cells in the infected host.

The loss of these cells leads to the progressive deterioration of the immune system, eventually resulting in the development of acquired immunodeficiency syndrome (AIDS), which is associated with multiple opportunistic infections.

Without treatment, HIV can progress to AIDS and may be fatal within a number of years. However, when appropriately managed with antiretroviral therapy (ART), HIV patients can achieve a near-normal lifeexpectancy.

Despite this, there is a continuing need to develop innovative new therapies for HIV, particularly among highly treated patients in whom HIV has developed resistance to one or more drugs.

Scope:

• The HIV pipeline is large, with more than 400 programs in active development. What proportion of these products are first-in-class? How does first-in-class innovation vary by development stage and molecular target class • -Approximately 50 first-in-class targets have been identified within the HIV pipeline. Among these, what is the distribution of host versus viral targets? Which of the host targets are considered to be most promising

Reasons to buy: • Understand the current disease landscape with an in-depth discussion of etiology, pathophysiology, disease classification and staging systems, epidemiology, and marketed therapies for HIV. • - Analyze the HIV pipeline, and stratify pipeline assets by stage of development, molecule type, and molecular target.

By Region North America

Europe

China

India

Japan

+91-8087042414 (Asia) | (+1) 646 781 7170 (Int'l) | help@grandresearchstore.com

Get in touch Call:

HIV: First-in-Class Therapies T arget Major Unmet Needs Includi ng Drug Resistance and Latency Reversal Download Free Sample

+91-8087042414 (Asia) (+1) 646 781 7170 (Int'l) E-mail: help@grandresearchstore.com

Sample includes 

Table Of Contents



List of Tables & Figures



Charts



Research Methodology